Table 4.
Individual changes in pulmonary function (FEV1 in % predicted) after 28 days of sinonasal therapy with tobramycin respective isotonic saline
| Pulmonary function (FEV1)
|
|||
|---|---|---|---|
| 28 days of DBPC treatment
|
28 days of facultative open-label treatment with tobramycin
|
||
| V1 (day 1) | V2 (day 30) | V3 (day 60) | |
| Tob/† | 109.0 | 92.1 | nd |
| Tob/tob | 64.3 | 63.1 | 62.0 |
| Tob/tob | 71.6 | 72.1 | 69.7 |
| Tob/tob | 102.5 | 98.5 | 101.2 |
| Tob/† | 86.0 | 93.8 | † |
| Tob/† | 83.0 | 80.0 | † |
| Iso sal/tob | 85.4 | 82.8 | 80.2 |
| Iso sal/tob | 66.3 | 64.2 | 66.7 |
| Iso sal/tob | 47.0 | 42.6 | 40.6 |
Note:
†
Patients not taking the second open-label treatment with tobramycin.
Abbreviations: FEV1, forced expiratory volume in 1 second; DBPC, double-blind, placebo-controlled; nd, not done; tob, tobramycin; iso sal, isotonic saline.